person · Reporting owner

PEREZ ROBERT J

Disclosed activity across 10 companies

Tapewire entity: 39727
SEC CIK: 0001263230

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMAG PHARMACEUTICALS, INC.AMAG · Entity 145305	Director	May 16, 2019	May 20, 2019
Cidara Therapeutics, Inc.CDTX · Entity 69639	Director	June 22, 2017	June 26, 2017
Cogent Biosciences, Inc.UMRX · Entity 3793	Director	June 14, 2019	June 18, 2019
Decoy Therapeutics Inc.FLKS · Entity 937	Director	July 26, 2017	July 27, 2017
Immunocore Holdings plcIMCR · Entity 4544	Director	January 02, 2024	January 02, 2024
Larimar Therapeutics, Inc.ZFGN · Entity 5634	Director	June 26, 2019	June 27, 2019
Rapport Therapeutics, Inc.RAPP · Entity 4394	Director	June 10, 2026	June 10, 2026
Third Harmonic Bio, Inc.THRD · Entity 76517	Director	March 06, 2023	March 08, 2023
Vir Biotechnology, Inc.VIR · Entity 4522	Director	May 22, 2023	May 24, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMAG PHARMACEUTICALS, INC.

Report date May 16, 2019 · Filed May 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	29,229	Reported balance After 2019-05-16 transaction · row 1 1 source row Row 1 · 2019-05-16 · Grant · Acquired 8,116 · Balance 29,229 F1: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2: Not applicable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.78 · Expires 2029-05-16	Direct	17,326	Reported balance After 2019-05-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-05-16 · Grant · Acquired 17,326 · Balance 17,326 F2: Not applicable. F4: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders.
Common StockSEC Table I · non-derivative	IndirectSee Footnote 3	4,400	Reported balance Holding disclosure · report date 2019-05-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,400 F3: Reflects 2,500 shares held by the Christine E. Perez 2004 Revocable Trust, dated February 25, 2004, as amended (the "Perez Trust") and 1,900 shares held by the Robert J. Perez 2004 Revocable Trust, dated February 25, 2004, as amended (the "Robert Perez Trust"). The Reporting Person's spouse is the trustee of the Perez Trust and the Reporting Person is the trustee of the Robert Perez Trust. The Reporting Person disclaims beneficial ownership of the securities held by the Perez Trust, except to the extent of his pecuniary interest therein. These 4,400 shares are held in trust for the benefit of the Reporting Person, his spouse and their descendants.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer.

F2: Not applicable.

F3: Reflects 2,500 shares held by the Christine E. Perez 2004 Revocable Trust, dated February 25, 2004, as amended (the "Perez Trust") and 1,900 shares held by the Robert J. Perez 2004 Revocable Trust, dated February 25, 2004, as amended (the "Robert Perez Trust"). The Reporting Person's spouse is the trustee of the Perez Trust and the Reporting Person is the trustee of the Robert Perez Trust. The Reporting Person disclaims beneficial ownership of the securities held by the Perez Trust, except to the extent of his pecuniary interest therein. These 4,400 shares are held in trust for the benefit of the Reporting Person, his spouse and their descendants.

F4: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders.

Cidara Therapeutics, Inc.

Report date June 22, 2017 · Filed June 26, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2027-06-21	Direct	11,000	Reported balance After 2017-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-22 · Grant · Acquired 11,000 · Balance 11,000 F1: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2018 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2018 annual meeting of stockholders.

Cogent Biosciences, Inc.

Report date June 14, 2019 · Filed June 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2029-06-14	Direct	7,131	Reported balance After 2019-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-14 · Grant · Acquired 7,131 · Balance 7,131 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2: This option is fully vested at time of grant.

Decoy Therapeutics Inc.

Report date July 26, 2017 · Filed July 27, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2027-07-26	Direct	12,000	Reported balance After 2017-07-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-07-26 · Grant · Acquired 12,000 · Balance 12,000 F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017.

Immunocore Holdings plc

Report date January 02, 2024 · Filed January 02, 2024

This filing explicitly reported no securities owned.

Larimar Therapeutics, Inc.

Report date June 26, 2019 · Filed June 27, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2029-06-26	Direct	27,000	Reported balance After 2019-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-26 · Grant · Acquired 27,000 · Balance 27,000 F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

Rapport Therapeutics, Inc.

Report date June 10, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10	Direct	15,200	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Third Harmonic Bio, Inc.

Report date March 06, 2023 · Filed March 08, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.83 · Expires 2032-10-25	Direct	0	Reported balance After 2023-03-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-06 · Disposition to issuer · Disposed 13,667 · Balance 0 F1: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2032-10-25	Direct	13,667	Reported balance After 2023-03-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-06 · Grant · Acquired 13,667 · Balance 13,667 F1: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F2: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date.

Vir Biotechnology, Inc.

Report date May 22, 2023 · Filed May 24, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,806	Reported balance After 2023-05-22 transaction · row 1 1 source row Row 1 · 2023-05-22 · Grant · Acquired 6,027 · Balance 15,806
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.74 · Expires 2033-05-21	Direct	12,054	Reported balance After 2023-05-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-05-22 · Grant · Acquired 12,054 · Balance 12,054

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 2,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.76 · Expires 2028-01-02	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 8,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 2,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2026 Filed Jun 10, 2026 21:52 UTC	Rapport Therapeutics, Inc. RAPP · Entity 4394	GrantStock Option (Right to Buy) · Derivative	15,200	$0.00 Strike: $35.21	$0.00	Disclosure SEC source: 0001193125-26-266147 · ownership.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 15,200 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 17, 2025 Filed Jun 18, 2025 20:15 UTC	Rapport Therapeutics, Inc. RAPP · Entity 4394	GrantStock Option (Right to Buy) · Derivative	10,925	$0.00 Strike: $10.95	$0.00	Disclosure SEC source: 0000950170-25-087900 · ownership.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,925 Underlying: Common Stock · 10,925 shares Expires 2035-06-17 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document
November 07, 2024 Filed Nov 8, 2024 00:00 UTC	Rapport Therapeutics, Inc. RAPP · Entity 4394	GrantStock Option (Right to Buy) · Derivative	29,756	$0.00 Strike: $26.90	$0.00	Disclosure SEC source: 0000950170-24-123610 · ownership.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,756 Underlying: Common Stock · 29,756 shares Expires 2034-11-07 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on November 7, 2025, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
May 22, 2023 Filed May 24, 2023 18:44 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	12,054	$0.00 Strike: $25.74	$0.00	Disclosure SEC source: 0001209191-23-031850 · doc4.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,054 Underlying: Common Stock · 12,054 shares Expires 2033-05-21 Read SEC document
May 22, 2023 Filed May 24, 2023 18:44 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	6,027	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031850 · doc4.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,806 Read SEC document
March 06, 2023 Filed Mar 8, 2023 17:06 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	GrantEmployee Stock Option (right to buy) · Derivative	13,667	Not disclosed Strike: $4.20	Not disclosed	Disclosure SEC source: 0001209191-23-017244 · doc4.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
March 06, 2023 Filed Mar 8, 2023 17:06 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	13,667	Not disclosed Strike: $17.83	Not disclosed	Disclosure SEC source: 0001209191-23-017244 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
October 26, 2022 Filed Oct 27, 2022 16:58 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	GrantStock Option (right to buy) · Derivative	13,667	$0.00 Strike: $17.83	$0.00	Disclosure SEC source: 0001209191-22-054730 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
May 23, 2022 Filed May 25, 2022 21:53 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	12,810	$0.00 Strike: $24.14	$0.00	Disclosure SEC source: 0001209191-22-031951 · doc4.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,810 Underlying: Common Stock · 12,810 shares Expires 2032-05-22 Read SEC document
May 23, 2022 Filed May 25, 2022 21:53 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	6,405	$0.00	$0.00	Disclosure SEC source: 0001209191-22-031951 · doc4.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,779 Read SEC document
May 21, 2021 Filed May 25, 2021 20:46 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	6,748	$0.00 Strike: $45.28	$0.00	Disclosure SEC source: 0001209191-21-035713 · doc4.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,748 Underlying: Common Stock · 6,748 shares Expires 2031-05-20 Read SEC document
May 21, 2021 Filed May 25, 2021 20:46 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	3,374	$0.00	$0.00	Disclosure SEC source: 0001209191-21-035713 · doc4.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,374 Read SEC document
May 21, 2020 Filed May 26, 2020 21:00 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	28,888	$0.00 Strike: $37.06	$0.00	Disclosure SEC source: 0001209191-20-032060 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,888 Underlying: Common Stock · 28,888 shares Expires 2030-05-21 Read SEC document
May 21, 2020 Filed Oct 13, 2020 23:12 UTC Amendment	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	24,567	$0.00 Strike: $37.06	$0.00	Disclosure SEC source: 0001209191-20-054739 · doc4a.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,567 Underlying: Common Stock · 24,567 shares Expires 2030-05-20 Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerRestricted Stock Units · Derivative	2,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-029446 · doc4.xml · derivative · entry 4 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	8,000	$0.00 Strike: $55.76	$0.00	Disclosure SEC source: 0000899243-19-029446 · doc4.xml · derivative · entry 3 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2028-01-02 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $81.53	$0.00	Disclosure SEC source: 0000899243-19-029446 · doc4.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:50 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	OtherCommon Stock	2,500	$114.50	$286,250.00	Disclosure SEC source: 0000899243-19-029446 · doc4.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document
October 10, 2019 Filed Oct 10, 2019 23:17 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	22,222	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001209191-19-052974 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222 Underlying: Common Stock · 22,222 shares Expires 2029-10-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on October [10], 2020, and the remainder vest in 24 equal monthly installments thereafter. Read SEC document
June 26, 2019 Filed Jun 27, 2019 23:36 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	27,000	$0.00 Strike: $1.25	$0.00	Disclosure SEC source: 0000899243-19-018481 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-06-26 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document
June 14, 2019 Filed Jun 18, 2019 20:25 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	7,131	$1.67 Strike: $2.43	$11,875.97	Disclosure SEC source: 0001209191-19-037689 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,131 Underlying: Common Stock · 7,131 shares Expires 2029-06-14 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
May 30, 2019 Filed Jun 3, 2019 20:18 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000058 · wf-form4_155959308804475.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document
May 30, 2019 Filed Jun 3, 2019 20:18 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-19-000058 · wf-form4_155959308804475.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document
May 16, 2019 Filed May 20, 2019 07:33 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantStock Option (Right to Buy) · Derivative	17,326	Not disclosed Strike: $10.78	Not disclosed	Disclosure SEC source: 0000792977-19-000107 · wf-form4_155835197338660.xml · derivative · entry 3 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,326 Underlying: Common Stock · 17,326 shares Expires 2029-05-16 F2 · price: Not applicable. F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders. Read SEC document
May 16, 2019 Filed May 20, 2019 07:33 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantCommon Stock	8,116	Not disclosed	Not disclosed	Disclosure SEC source: 0000792977-19-000107 · wf-form4_155835197338660.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,229 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document
April 01, 2019 Filed Apr 3, 2019 20:29 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	4,369	$2.72 Strike: $4.40	$11,877.13	Disclosure SEC source: 0001209191-19-023130 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,369 Underlying: Common Stock · 4,369 shares Expires 2029-04-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
January 24, 2019 Filed Jan 29, 2019 00:01 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	5,717	$0.00 Strike: $4.38	$0.00	Disclosure SEC source: 0000899243-19-002064 · doc4.xml · derivative · entry 3 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,717 Underlying: Common Stock · 5,717 shares Expires 2029-01-24 F3 · derivative.exercise_date: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2019 on a quarterly basis in arrears. Read SEC document
January 24, 2019 Filed Jan 29, 2019 00:01 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantCommon Stock	4,423	$4.38	$19,372.74	Disclosure SEC source: 0000899243-19-002064 · doc4.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,322 F1 · shares: The common stock was acquired in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Restricted Stock Unit Award and the restrictions lapse over a period of one year starting January 1, 2019 on a quarterly basis in arrears. Each restricted stock unit represents a contingent right to receive one share of Zafgen, Inc. common stock. Read SEC document
January 03, 2019 Filed Jan 4, 2019 21:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	1,000	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000004 · wf-form4_154663584200619.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F2 · derivative.exercise_date: On January 3, 2018, the reporting person was granted 3,000 restricted stock units that vest in three equal annual installments beginning January 3, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F2 · derivative.expiration_date: On January 3, 2018, the reporting person was granted 3,000 restricted stock units that vest in three equal annual installments beginning January 3, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 03, 2019 Filed Jan 4, 2019 21:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-19-000004 · wf-form4_154663584200619.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. Read SEC document
January 02, 2019 Filed Jan 4, 2019 21:55 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	4,397	$2.70 Strike: $4.47	$11,871.90	Disclosure SEC source: 0001209191-19-002045 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,397 Underlying: Common Stock · 4,397 shares Expires 2029-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
October 01, 2018 Filed Oct 3, 2018 21:16 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	1,910	$6.22 Strike: $10.37	$11,880.20	Disclosure SEC source: 0001209191-18-053967 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,910 Underlying: Common Stock · 1,910 shares Expires 2028-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
July 26, 2018 Filed Sep 26, 2018 22:46 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	1,361	$8.72 Strike: $14.57	$11,867.92	Disclosure SEC source: 0001209191-18-052363 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361 Underlying: Common Stock · 1,361 shares Expires 2028-07-26 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
June 07, 2018 Filed Jun 8, 2018 16:11 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantStock Option (Right to Buy) · Derivative	7,543	$0.00 Strike: $24.45	$0.00	Disclosure SEC source: 0000792977-18-000041 · wf-form4_152848864906632.xml · derivative · entry 3 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,543 Underlying: Common Stock · 7,543 shares Expires 2028-06-07 F2 · price: Not applicable. F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders. Read SEC document
June 07, 2018 Filed Jun 8, 2018 16:11 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantCommon Stock	3,578	$0.00	$0.00	Disclosure SEC source: 0000792977-18-000041 · wf-form4_152848864906632.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,113 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document
June 06, 2018 Filed Jun 7, 2018 21:33 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $6.79	$0.00	Disclosure SEC source: 0000899243-18-015550 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 6, 2019 or the date of the 2019 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document
May 30, 2018 Filed Jun 1, 2018 12:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000061 · wf-form4_152785725185875.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document
May 30, 2018 Filed Jun 1, 2018 12:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantStock Option (right to buy) · Derivative	4,000	$0.00 Strike: $81.53	$0.00	Disclosure SEC source: 0001609351-18-000061 · wf-form4_152785725185875.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F1 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document
January 03, 2018 Filed Jan 4, 2018 22:22 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000006 · wf-form4_151510454329592.xml · derivative · entry 2 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning January 3, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning January 3, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 03, 2018 Filed Jan 4, 2018 22:22 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $55.76	$0.00	Disclosure SEC source: 0001609351-18-000006 · wf-form4_151510454329592.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: 33% vests January 3, 2019 and the remainder vests in equal annual installments over the following two years. Read SEC document
January 03, 2018 Filed Jan 5, 2018 21:59 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	9,421	$0.00 Strike: $5.18	$0.00	Disclosure SEC source: 0000899243-18-000591 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,421 Underlying: Common Stock · 9,421 shares Expires 2028-01-03 F1 · derivative.exercise_date: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2018 on a quarterly basis in arrears. Read SEC document
July 26, 2017 Filed Jul 27, 2017 12:57 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0001615219-17-000059 · wf-form4_150116026485727.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-07-26 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. Read SEC document
June 22, 2017 Filed Jun 26, 2017 21:10 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $6.90	$0.00	Disclosure SEC source: 0001209191-17-041858 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-21 F1 · shares: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2018 annual meeting of stockholders. F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2018 annual meeting of stockholders. Read SEC document
June 21, 2017 Filed Jun 23, 2017 20:07 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	14,500	$0.00 Strike: $3.95	$0.00	Disclosure SEC source: 0000899243-17-017069 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 21, 2018 or the date of the 2018 annual meeting of stockholders, subject to the director's continued service on the board of directors. Read SEC document
May 18, 2017 Filed May 22, 2017 19:05 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantStock Option (Right to Buy) · Derivative	10,110	Not disclosed Strike: $19.25	Not disclosed	Disclosure SEC source: 0001179110-17-007781 · edgar.xml · derivative · entry 3 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common Stock · 10,110 shares Expires 2027-05-18 F2 · price: Not applicable. F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders. Read SEC document
May 18, 2017 Filed May 22, 2017 19:05 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantCommon Stock	4,545	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-007781 · edgar.xml · nonDerivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,535 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document
February 13, 2017 Filed Feb 15, 2017 01:16 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	13,289	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0000899243-17-004101 · doc4.xml · derivative · entry 1 PEREZ ROBERT J · CIK 0001263230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,289 Underlying: Common Stock · 13,289 shares Expires 2027-02-13 F1 · derivative.exercise_date: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2017 on a quarterly basis in arrears. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.